TY - JOUR
T1 - Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis c virus genotype 1 infection
AU - Marcellin, Patrick
AU - Cooper, Curtis
AU - Balart, Luis
AU - Larrey, Dominique
AU - Box, Terry
AU - Yoshida, Eric
AU - Lawitz, Eric
AU - Buggisch, Peter
AU - Ferenci, Peter
AU - Weltman, Martin
AU - Labriola-Tompkins, Emily
AU - Le Pogam, Sophie
AU - Nájera, Isabel
AU - Thomas, Denise
AU - Hooper, Gregory
AU - Shulman, Nancy S.
AU - Zhang, Ying
AU - Navarro, Mercidita T.
AU - Lim, Chin Yin
AU - Brunda, Michael
AU - Terrault, Norah A.
AU - Yetzer, Ellen S.
N1 - Funding Information:
Funding This research was funded by F. Hoffmann-La Roche Ltd . Support for third-party writing assistance for this manuscript was provided by F. Hoffmann-La Roche Ltd.
PY - 2013/10
Y1 - 2013/10
N2 - Background & Aims The combination of a hepatitis C virus (HCV) protease inhibitor, peginterferon, and ribavirin is the standard of care for patients with HCV genotype 1 infection. We report the efficacy and safety of response-guided therapy with danoprevir (a potent second-generation protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these patients. Methods Treatment-naïve patients (N = 237) were randomly assigned to groups given 12 weeks of danoprevir (300 mg every 8 hours; 600 mg every 12 hours, and 900 mg every 12 hours) or placebo plus peginterferon alfa-2a and ribavirin, followed by peginterferon alfa-2a and ribavirin. Patients given danoprevir who had an extended rapid virologic response (eRVR4-20: HCV RNA <15 IU/mL during weeks 4-20) stopped therapy at week 24; those without an eRVR 4-20 continued therapy to 48 weeks. Patients who were given placebo received 48 weeks of peginterferon alfa-2a and ribavirin. The primary efficacy end point was sustained virologic response (SVR: HCV RNA <15 IU/mL after 24 weeks without treatment). Results Rates of SVR were higher among patients given danoprevir 300 mg (68%), 600 mg (85%), and 900 mg (76%) than placebo (42%) (95% confidence interval: 26%-59%). Seventy-nine percent of patients given danoprevir 600 mg had an eRVR4-20; among these, 96% had an SVR. Serious adverse events were reported in 7% to 8% of patients given danoprevir and 19% given placebo. Four patients given danoprevir (1 patient in the 600-mg group and 3 in the 900-mg group) had reversible, grade 4 increases in alanine aminotransferase, which led to early discontinuation of the 900-mg arm of the study. Conclusions The combination of danoprevir, peginterferon alfa-2a, and ribavirin leads to high rates of SVR in patients with HCV genotype 1 infection, but high doses of danoprevir can lead to grade 4 increases in alanine aminotransferase. Studies of lower doses of danoprevir with ritonavir, to reduce overall danoprevir exposure while maintaining potent antiviral activity, are underway; Clinicaltrials.gov number, NCT00963885.
AB - Background & Aims The combination of a hepatitis C virus (HCV) protease inhibitor, peginterferon, and ribavirin is the standard of care for patients with HCV genotype 1 infection. We report the efficacy and safety of response-guided therapy with danoprevir (a potent second-generation protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these patients. Methods Treatment-naïve patients (N = 237) were randomly assigned to groups given 12 weeks of danoprevir (300 mg every 8 hours; 600 mg every 12 hours, and 900 mg every 12 hours) or placebo plus peginterferon alfa-2a and ribavirin, followed by peginterferon alfa-2a and ribavirin. Patients given danoprevir who had an extended rapid virologic response (eRVR4-20: HCV RNA <15 IU/mL during weeks 4-20) stopped therapy at week 24; those without an eRVR 4-20 continued therapy to 48 weeks. Patients who were given placebo received 48 weeks of peginterferon alfa-2a and ribavirin. The primary efficacy end point was sustained virologic response (SVR: HCV RNA <15 IU/mL after 24 weeks without treatment). Results Rates of SVR were higher among patients given danoprevir 300 mg (68%), 600 mg (85%), and 900 mg (76%) than placebo (42%) (95% confidence interval: 26%-59%). Seventy-nine percent of patients given danoprevir 600 mg had an eRVR4-20; among these, 96% had an SVR. Serious adverse events were reported in 7% to 8% of patients given danoprevir and 19% given placebo. Four patients given danoprevir (1 patient in the 600-mg group and 3 in the 900-mg group) had reversible, grade 4 increases in alanine aminotransferase, which led to early discontinuation of the 900-mg arm of the study. Conclusions The combination of danoprevir, peginterferon alfa-2a, and ribavirin leads to high rates of SVR in patients with HCV genotype 1 infection, but high doses of danoprevir can lead to grade 4 increases in alanine aminotransferase. Studies of lower doses of danoprevir with ritonavir, to reduce overall danoprevir exposure while maintaining potent antiviral activity, are underway; Clinicaltrials.gov number, NCT00963885.
KW - Danoprevir (RG7227) Hepatitis C Virus Sustained Virologic Response Response-Guided Therapy
UR - http://www.scopus.com/inward/record.url?scp=84884411153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884411153&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2013.06.051
DO - 10.1053/j.gastro.2013.06.051
M3 - Article
C2 - 23811112
AN - SCOPUS:84884411153
SN - 0016-5085
VL - 145
SP - 790-800.e3
JO - Gastroenterology
JF - Gastroenterology
IS - 4
ER -